folate is quantified by measurement of unoccupied binding sites on the folate-binding protein (1 ). The calibrators for the assay cover the range 0 -45 nmol/L.
In the absence of an internationally accepted reference method or material (2 ) , we have compared the performance of the AxSYM method with two methods commonly used nationally and internationally, namely the SimulTrac-SNB (ICN Pharmaceuticals Inc.) and the Quantaphase II (Bio-Rad Laboratories). Both of these are competitive RIAs.
We selected 100 patient samples from among serum specimens received in the laboratory for determination of serum folate to obtain a concentration range up to 68 nmol/L (30 g/L) as measured by the SimulTrac-SNB assay. The sera were frozen at Ϫ20°C until analysis. After thawing, all three comparison assays were performed on the same day. Sample collection procedures were in agreement with the guidelines of the hospital's Ethical Commission.
Results by the two comparison methods agreed well, with Passing--Bablok (3 ) analysis yielding the following regression equation: y (Quantaphase II) ϭ 0.93x (SimulTrac) Ϫ 0.23 nmol/L; r ϭ 0.942; n ϭ 100. In comparisons of the AxSYM assay with the two isotopic methods, the regression plots (Fig. 1, A and C) and the Bland-Altman (4 ) bias plots (Fig. 1, B and D) suggested regression lines with three different slopes. Above 23 nmol/L (10 g/L) as measured by the comparison methods, the AxSYM method produced a flat response. Linearity of the assays was tested by mixing a very high (45 nmol/L) and a very low sample (1 nmol/L) to obtain increasing concentrations in steps of 10%. Each mixture was tested in duplicate, and statistical evaluations were made by linear regression analysis. The AxSYM method showed significant nonlinearity (Fig. 1E) . The analogous plots for SimulTrac and Quantaphase II were linear between 10% and 100% of high sample, with r 2 ϭ 0.996 and r 2 ϭ 0.999, respectively. The measured/expected concentration was between 99% and 101% at the highest values.
Although the manufacturer's product insert states that "some samples in the upper region of the dynamic range may read lower in the AxSYM assay when compared with some other commercial assays", our data suggest that samples Ͼ23 nmol/L (the middle of the dynamic range) routinely read lower in the AxSYM assay than in either of the two widely used methods. In agreement with the manufacturer's warning that "serum and plasma specimens from patients with renal impairment may exhibit varying degrees of falsely depressed values", marked disagreement was observed between the AxSYM and the comparison methods for the serum specimens of chronic renal failure patients (indicated by the numeral 1 in Fig. 1 ).
Similar apparent limitations in the dynamic range of the AxSYM method appeared to be present when folate was measured in erythrocyte hemolysates. At concentrations Ͼ906 nmol/L (Ͼ400 g/L) with the Simul-Trac method and Ͼ453 nmol/L (Ͼ200 g/L) with the Quantaphase II method, the regression lines were found to bend. We saw no erythrocyte folate results Ͼ1360 nmol/L (Ͼ600 g/L) by the AxSYM method, even in patients known to be taking folate supplements regularly for a protracted period of time.
We conclude that the dynamic range of the AxSYM folate assay does not extend above 23 nmol/L (10 g/L) for serum folate and not above 1360 nmol/L (600 g/L) for erythrocyte folate. This is only half the dynamic range of other proteinbinding folate assays.
